长期小剂量阿奇霉素联合布地奈德／福莫特罗治疗Ⅲ、Ⅳ级COPD稳定期患者的疗效

摘要

目的：探讨长期小剂量阿奇霉素联合布地奈德／福莫特罗对Ⅲ、Ⅳ级慢性阻塞性肺疾病（COPD）稳定期患者的安全性与疗效分析。方法：采用前瞻性随机对照的研究方法，选择我院87例Ⅲ、Ⅳ级COPD稳定期患者作为研究对象，随机分为对照组（布地奈德／福莫特罗160μg／4．5μg 每吸，1吸／次，2次／d），联合治疗组（布地奈德／福莫特罗160μg／4．5μg每吸，1吸／次，2次／d ＋阿奇霉素250 mg，1次／d。观察两组治疗3、6个月后 PEF、FEV1、FEV1／FVC、mMRC、6MWT，急性加重次数。结果：联合治疗组在3、6个月后的PEF、FEV1、FEV1／FVC改善较对照组显著（P ＜0．05）；两组在3个月后的 mMRC、6MWT、急性加重次数改善程度相仿（P ＞0．05），6个月后联合治疗组较对照组改善显著（P ＜0．05）。结论：长期小剂量阿奇霉素联合布地奈德／福莫特罗治疗较单一吸入布地奈德／福莫特罗能明显改善患者相关的肺功能指标，且随着用药时间延长，联合治疗较单一治疗更能显著改善相关临床症状，并降低急性加重次数。%Objective To investigate the safety and efficacy of long-term low doses of Azithromycin combined with Budesonide/Fomoterol in the treatment of stable Ⅲ to Ⅳ COPD patients. Methods Collect the confirmed COPD patients of our hospital, they were randomly divided into two groups: the control group (160μg/ 4.5 μg, Bid), the joint group (160 μg/ 4.5 μg/ Bid + azithromycin 250 mg qd). Then Observe the PEF, FEV1, FEV1/FVC, mMRC, 6 MWT, AECOPD of the two groups after treatment for 3 months and 6 months. Results the index of PEF, FEV1, FEV1/FVC of joint group improved more significantly (P < 0.05) than control group after 6 months; the mMRC, 6 MWT, AECOPD, of the two groups improve the similar degree in terms of 3 months (P > 0.05), joint group improved more significantly than control group after 6 months (P < 0.05). Conclusion the therapy of Long-term low doses of azithromycin combined with Budesonide/Fomoterol can more significantly improve lung function index , as the treatment time extended , it can significantly improve clinical symptoms ,reduce the number of exacerbations than single inhaled Budesonide/Fomoterol .